- Home
- WKSP vs CMMB Comparison
WKSP vs CMMB Comparison
Compare WKSP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- CMMB
- Stock Information
- Founded
- WKSP 2003
- CMMB 2004
- Country
- WKSP United States
- CMMB Israel
- Employees
- WKSP N/A
- CMMB N/A
- Industry
- WKSP Auto Parts:O.E.M.
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- WKSP Consumer Discretionary
- CMMB Health Care
- Exchange
- WKSP Nasdaq
- CMMB Nasdaq
- Market Cap
- WKSP 14.6M
- CMMB 13.7M
- IPO Year
- WKSP N/A
- CMMB N/A
- Fundamental
- Price
- WKSP $3.41
- CMMB $3.41
- Analyst Decision
- WKSP Strong Buy
- CMMB Strong Buy
- Analyst Count
- WKSP 3
- CMMB 2
- Target Price
- WKSP $12.83
- CMMB $26.50
- AVG Volume (30 Days)
- WKSP 461.3K
- CMMB 263.1K
- Earning Date
- WKSP 11-12-2025
- CMMB 11-13-2025
- Dividend Yield
- WKSP N/A
- CMMB N/A
- EPS Growth
- WKSP N/A
- CMMB N/A
- EPS
- WKSP N/A
- CMMB N/A
- Revenue
- WKSP $12,395,166.00
- CMMB N/A
- Revenue This Year
- WKSP $159.83
- CMMB N/A
- Revenue Next Year
- WKSP $84.48
- CMMB N/A
- P/E Ratio
- WKSP N/A
- CMMB N/A
- Revenue Growth
- WKSP 232.13
- CMMB N/A
- 52 Week Low
- WKSP $2.44
- CMMB $2.39
- 52 Week High
- WKSP $12.00
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- WKSP 48.29
- CMMB 67.36
- Support Level
- WKSP $3.40
- CMMB $3.23
- Resistance Level
- WKSP $3.70
- CMMB $3.50
- Average True Range (ATR)
- WKSP 0.33
- CMMB 0.20
- MACD
- WKSP -0.01
- CMMB 0.03
- Stochastic Oscillator
- WKSP 34.94
- CMMB 85.26
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.